EMFLAZA® (deflazacort) is a corticosteroid that demonstrates anti-inflammatory and immunosuppressant effects.

Status & Important Information

• EMFLAZA® is indicated for the treatment of Duchenne muscular dystrophy in patients 2 years of age and older (download EMFLAZA® label & prescribing information).
• EMFLAZA (deflazacort) is an oral corticosteroid that reduces muscle inflammation and slows muscle weakness in individuals with Duchenne. EMFLAZA is the brand name and deflazacort is the generic name.
• EMFLAZA (deflazacort) is not dependent upon genetic variants or other factors like ambulation and is available for individuals ages 2 years and older.
• You should never stop taking EMFLAZA (deflazacort) abruptly and always consult with your doctor if thinking about stopping or switching.

For additional resources regarding eligibility and access, view PPMD’s Insurance Access & Coverage Roadmap.

Sponsor

This program is sponsored by PTC Therapeutics.

Related Studies

For information regarding current or upcoming clinical trials please visit our Explore Clinical Trials Page.

Media Library